Showing 3891-3900 of 6411 results for "".
- Candela and Vascular Birthmark Foundation Offer Pro Bono Laser Treatments for Patients in Needhttps://practicaldermatology.com/news/candela-and-vascular-birthmark-foundation-offer-pro-bono-laser-treatments-for-patients-in-need/2457593/Candela Corporation is partnering with the Vascular Birthmarks Foundation (VBF) to provide pro-bono Vbeam laser treatments to children and adults with birthmarks, port wine stains and other vascular related skin conditions as a kickoff to the VBF 18th A
- ASDS 2018 Survey: Patients Spend About $100 Per Month on Skin Care Productshttps://practicaldermatology.com/news/asds-2018-survey-patients-spend-about-100-per-month-on-skin-care-products/2457608/Almost 70 percent of consumers are considering a cosmetic treatment, and more than half would prefer to pay more up front to lower their annual skin care costs, according to the 2018 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Der
- Escalier Biosciences' Doses First PsO Patient with ESR-114; Announces Clinical Advisory Boardhttps://practicaldermatology.com/news/escalier-biosciences-doses-first-patient-with-esr-114-announces-clinical-advisory-board/2457652/The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates o
- Pulse Biosciences: First Patient Treated in BCC Studyhttps://practicaldermatology.com/news/pulse-biosciences-first-patient-treated-in-bcc-study/2457653/The first patient has been treated in a clinical study to evaluate Nano-Pulse Stimulation (NPS) from Pulse Biosciences, Inc. for
- FDA Committee Recommends Approval of Paratek's Omadacyclinehttps://practicaldermatology.com/news/fda-committee-recommends-approval-of-parateks-omadacycline/2457656/The Antimicrobials Drug Advisory Committee of the FDA voted in favor of the approval of intravenous (IV) and oral omadacycline for the treatment of acute bacterial skin and skin structure infections (ABSSSI) (17-1) and community-acquired bacterial pneumonia (CABP) (14-4). Paratek Pharmaceuticals,
- Skin Cancer Risk Varies Based on Organ Transplant Patients' Skin Tonehttps://practicaldermatology.com/news/skin-cancer-risk-varies-based-on-organ-transplant-patients-skin-tone/2457673/Dermatologists must know how to evaluate organ transplant patients’ unique risk factors for skin cancer and counsel these patients accordingly. “Individuals who receive organ transplants need to take immunosuppressive medications for the rest of their lives, and this makes it
- Pulse Biosciences: First Patients Treated in Study of Sebaceous Hyperplasia Lesionshttps://practicaldermatology.com/news/pulse-biosciences-first-patients-treated-in-study-of-sebaceous-hyperplasia-lesions/2457682/Pulse Biosciences, Inc. says the first patients have been treated in its multi-center study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous Hyperplasia (SH). SH is an unsightly benign skin lesion that typically appears on facial skin an
- Colorescience Receives Patent for Even Up Clinical Pigment Corrector Formulationhttps://practicaldermatology.com/news/colorescience-receives-patent-for-even-up-clinical-pigment-corrector-formulation/2457687/The US Patent and Trademark Office (USPTO) has granted a patent for Colorescience’s LUMIRA™ formulation, a clinically tested, highly effective complex that addresses the appearance of skin discoloration, found in the 3-in-1 treatment product, Even Up® Clinical Pigment P
- PAH after Cryolipolysis May Not Be So 'Rare'https://practicaldermatology.com/news/pah-after-cryolipolysis-may-not-be-so-rare/2457707/Paradoxical adipose hyperplasia (PAH) after cryolipolysis may be more common than previously thought according to a paper in the July issue of Plastic and Reconstructive Surgery®. While PAH can be treated successfully
- First EB Patient Enrolled in PK Study of Diacerein 1% Ointmenthttps://practicaldermatology.com/news/first-eb-patient-enrolled-in-pk-study-of-diacerein-1-ointment/2457716/The first patient has been enrolled in a new Phase 1 study evaluating the pharmacokinetics (PK) and safety of Castle Creek Pharmaceuticals’ diacerein 1% ointment (CCP-020) under maximum use conditions in patients with epidermolysis bullosa (EB)